samples from 151 patients with multiple myeloma (MM), including 117 patients evaluated at diagnosis, were collected for cytogenetic analysis. A total of 129 patients had assessable metaphases (100 patients at diagnosis). Cytogenetic studies were performed on BM cells after longterm cultures (6 days) with stimulation of cultures by granulocyte-macrophage colony-stimulating factor (GM-CSF), GM-CSF plus interleukin (IL)-6, IL-3 plus IL-6, or GM-CSF plus IL-3 plus IL-6 t o improve myeloma cell growth, and 91 patients had an additional unstimulated culture. Sixty-six patients (51%) had cytogenetic abnormalities, including 47 of 100 patients at diagnosis (47%) and 17 of 24 patients at relapse (71%; P = .04). The aberration rate increased with stage (P = .007), BM plasmacytosis ( P = .003), p2 microglobulin level (P = .001), C-reactive protein (CRP) level ( P = .001),
Between December 1990 and January 1994, bone marrow (BM) samples from 151 patients with multiple myeloma (MM), including 117 patients evaluated at diagnosis, were collected for cytogenetic analysis. A total of 129 patients had assessable metaphases (100 patients at diagnosis). Cytogenetic studies were performed on BM cells after longterm cultures (6 days) with stimulation of cultures by granulocyte-macrophage colony-stimulating factor (GM-CSF), GM-CSF plus interleukin (IL)-6, IL-3 plus IL-6, or GM-CSF plus IL-3 plus IL-6 t o improve myeloma cell growth, and 91 patients had an additional unstimulated culture. Sixty-six patients (51%) had cytogenetic abnormalities, including 47 of 100 patients at diagnosis (47%) and 17 of 24 patients at relapse (71%; P = .04). The aberration rate increased with stage (P = .007), BM plasmacytosis ( P = .003), p2 microglobulin level (P = .001), C-reactive protein (CRP) level ( P = .001),
and Ki-67 ( P = .007). The abnormality detection rate was higher in stimulated than unstimulated cultures, and the difference was statistically significant ( P < . O I L Hyperdiploidy was observed in 39 patients (30% of patients with an assessable karyotype) and hypodiploidy in 19 patients (15%).
YTOGENETIC STUDIES performed in multiple myeloma (MM) have been relatively rare and difficult because of the low proliferation rate of plasma cells.
In previously reported series, the incidence of abnormal karyotypes has varied from 20% to 60%, with a median of 30% to 40%.' In patients with newly diagnosed MM, abnormal karyotypes were observed in 18% of successfully analyzed patients in the series reported by Dewald et al,* 26% in the series reported by Weh et a13 and 36% in the series reported by Could et aL4 Even if some of these variations could be accounted for by sampling errors, the role of the addition of cytokines in the cultures of plasma cells may be crucial. Indeed, concerning the cytokine network in human MM, there is now strong evidence that interleukin-6 (IL-6) is the major growth factor for malignant plasmablastic cells in vitro and in vivo. In patients with MM, an overproduction of IL-6 is found in about one third of patients at diagnosis and C Among numeric changes, gains predominantly involved chromosomes 3, 5, 7, 9, 11, 15, 19 and losses, chromosomes 8,13,14, and X. The most frequent loss was loss of chromosome 13, observed in 22 patients (15%), including 18 patients at diagnosis (12%). We observed frequent structural changes of chromosomes 1 (15%) and 14 (10%) but also a 5% incidence of 19q13 abnormality and two patients with translocation t~l ; l 6~~p l l ; p l l ) .
By using the proportional hazard univariate model, patients with abnormal karyotypes were demonstrated t o have 2.5-fold greater chance of death than patients with normal karyotypes ( P < .014). Despite a multivariate approach with the same model. the respective roles of karyotype abnormality, age, stage, and p2 microglobulin level could not be clearly ascertained. From these results we conclude that cytogenetic analysis using stimulation of cultures by cytokine(s1 may be a promising method t o identify about 50% of cytogenetic abnormalities in patients with newly diagnosed MM. Cytogenetic analysis may help t o define a high-risk population that would benefit from intensive therapeutic approaches. is associated with poor prognosis.5 In addition, anti-IL-6 therapies in patients with terminal disease block myeloma cell proliferation in vitro.' It has also been recently established that hematopoietic cytokines such as granulocytemacrophage colony-stimulating factor (GM-CSF) and IL-3 synergize with IL-6, through IL-6-related mechanisms, to support myeloma g r~w t h .~ Nevertheless, some controversy remains regarding the exact role of IL-6 in MM. Some investigators have identified a correlation between high levels of IL-6 and low tumor mass and have favored the role of IL-6 in the promotion of plasma cell maturation.x On the other hand, the clinical impact of an abnormal cytogenetics in myeloma patients at diagnosis has not been so far established in a large series with respect to other known prognostic factors in myeloma. In a preliminary report, we reported a 42.5% incidence of cytogenetic abnormalities in patients at diagnosis using cytokine stimulation of cultures with IL-6, IL-3. and GM-CSF.' This previous report was considered a successful attempt to increase the detection rate of cytogenetic abnormalities in MM using growth factors of plasma cells.7."'.l I This work has now been extended, and we report here our updated results on 15 I patients including I 17 patients at diagnosis, with an analysis of the prognostic value of cytogenetics in MM.
MATERIALS AND METHODS
Between December 1990 and January 1994, 159 bone marrow (BM) samples from 151 patients with MM diagnosed in our center according to Dune" were karyotyped. BM cells ( I mL) were mixed with RPMI medium (1 mL) and layered on 3 mL of Nycoprep (Nicomed Pharma AS, Oslo, Norway). The cells were then centrifuged at 3,500 rpm for 30 minutes. The interface region was aspirated and washed twice in RPMI medium. BM cells were cultured for 6 days in Chang medium (Clini Sciences, Irvine Scientific Inc. Santa Ana, CA) supplemented with 20% fetal calf serum and growth factor(s).' Cultures were stimulated with GM-CSF (Sandoz, Basel, Chromosomes were identified by RHG banding and were classified according to the International System for Cytogenetic Nomenclature." A karyotype was considered normal when no clonal abnormality was detected among 10 metaphases examined. Patients with less than 10 metaphases and no clonal abnormality were considered failures.
DNA content of plasma cells (DNA index) was determined after Feulgen reaction using computerized image analysis, as previously described.14 DNA index was calculated as the ratio of the mean optical density of plasma cell nuclei to the mean optical density of lymphocyte nuclei, using the computerized image analyzer Biocom (Biocom, Lyon, France). Determination of the plasma cell growth fraction with Ki-67 using a double immunoenzymatic technique was performed as previously described by Lokhorst et as well as the percentage of spotted cells (in 26 patients). All of the biologic evaluations were performed at the time the karyotype was determined. For 117 patients, referred to as diagnosis patients, the karyotype was determined at diagnosis in 74 patients and shortly after diagnosis in 43 patients, with the disease being stable (nonevolutive MM) and with a median delay-to-diagnosis of 18 days (range, 1 day to 16 months). For four other patients, the karyotype was determined more than 2 years after diagnosis and for one patient, at the time of evolution in myelodysplastic syndrome. For 29 patients, the karyotype was determined at the time of relapse.
Tumor mass and response to therapy were defined by standard criteria.".'* Statistical methods. Description of study samples was performed for all patients at first evaluation (N = 151). The relationship between the karyotype evaluation (normaVabnormal) and the other items was established through the chi-squared test for categorical data and for continuous variables after categorization according to the median value and with the Mann-Whitney test for continuous variables." The relationship between DNA content and chromosome number was evaluated in patients with assessable karyotype at diagnosis, except for patients with 46 chromosomes, and tested through Spearman nonparametric c~rrelation.'~ In 91 patients who were evaluated for cytogenetic analysis with and without stimulation, the effect of stimulation on abnormality detection was tested by paired chi-squared method."
Analysis was performed June 1, 1994, with an observation time ranging from 5 months to 41 months. Three patients were lost to follow-up during the study period. The following initial parameters were analyzed in all patients at diagnosis (N = 117) and in patients at diagnosis with an assessable karyotype (N = 100) for their prognostic value on survival: age, sex, stage, substage, BM plasmacytosis, M-component isotype, type of light chain, p2 microglobulin level, lactic0 dehydrogenase (LDH) level, C-reactive protein (CRP), Ki-67, DNA content, karyotype, number of chromosomes, presence of monosomy 13, presence of structural abnormalities of chromosome 14, treatment, and response to chemotherapy. Comparison of the characteristic distributions between patients with an assessable karyotype (N = 100) and those whose karyotype could not be interpreted (N = 17) was performed by the Mann-Whitney or chi-squared tests.'' In the survival analysis, continuous variables were either used after logarithmic transformation, or categorized on logical grounds (usual cut-off value) or relative to the median value. Survival curves, globally or for each category of a studied variable, plus IL-6; 17, IL-6 PIUS IL-3; 14, GM-CSF PIUS IL-3 plus IL-6 were calculated using the Kaplan-Meier method'' and compared using the log-rank test." Relative risk of death (RR), mean values, and 95% confidence intervals (95% CI) were estimated using the Cox model.zz Parameters significant at the .20 level were introduced in the Cox model with forward selection?' All analyses were performed with SPSS and BMDP?3.24
RESULTS

Description ofthe population.
Of the 151 patients, cytogenetic analysis was unsuccessful in 22 patients (15%), and 129 patients had assessable metaphases. Seven patients had more than one karyotype at different time points during follow up, resulting in a total of 159 samples (six patients with two karyotypes and one patient with three). These secondary analyses were performed at time of evolution from stage I to stage IYIII disease in five patients, in stable stage I disease in one patient, and in a stage I1 patient, refractory to chemotherapy. The results of these second or third evaluations were always identical to the first karyotype. Among the 22 patients with cytogenetic analysis failure, 13 had less than five metaphases observed and nine had 5 to 10 metaphases observed. Seventeen of these patients had newly diagnosed multiple myeloma; and five patients were in relapse. The failure rate was greater in the first year of the study: 10 of 36 patients (28%) before March 1992 and 12 of 115 patients (10%) after March 1992 ( P = .01). The group of 129 patients with an assessable karyotype included 100 patients at diagnosis, 24 patients in relapse, four patients karyotyped while in stage I for more than 2 years, and one patient karyotyped at time of evolution in myelodysplastic syndrome. Two patients had de novo plasma cell leukemia (PCL). Four patients had an associated, biopsy-proven amyloidosis, and three patients had an associated myelodysplastic syndrome. The characteristics of the whole population are given in Table 1 . Among the 117 patients at diagnosis, 92 patients required prompt, specific treatment. Sixty-nine patients were treated with conventional chemotherapy: melphalan-prednisone, 26 patients; melphalan-prednisone-recombinant alpha interferon, 19 patients; VMCP-VBAP (vincristine, melphalan, cytoxan, and prednisone combined with vincristine, BCNU, adriamycin, and prednisone), 13 patients; VAD (vincristine, adriamycin, and dexamethasone), four patients; dexamethasone, four patients; and VMBCP, three patients. Twenty-three patients received an intensive treatment: high-dose melphalan [HDM; 140 mg/m2, intravenously (IV)], 13 patients; autologous BM or blood stem-cell transplantation (ABMT or ABSCT, respectively), five patients; HDM followed by ABMT, three patients; and allogeneic BM transplantation, two patients.
Cytogenetic study. Sixty-six patients (51%) had an abnormal karyotype: 47 of 100 (47%) at diagnosis and 17 of 24 patients (71%) at relapse ( P = .04; one of four patients karyotyped while in stage I for more than 2 years had an abnormal karyotype, and one of one patient at the time of evolution in myelodysplastic syndrome). As shown in Table  2 , the abnormality rate increased with stage, BM plasmacytosis, p2 microglobulin and CRP levels, Ki-67, and requirement for chemotherapy. Abnormality rate was unrelated to all the other factors, including the type of treatment (23) 86 (57) 2 (1) 97 (84) 18 (16) 117 (77) 25 (17) 9 (6) 85 (56) 40 (26) 21 (14) 4 (3) 1 (1) 92 (61) 59 (39) 68 ( (conventional v intensive treatment; P = .218). All results were confirmed when using biologic continuous variables (data not shown).
Abnormal karyotypes were usually complex with multiple numeric and structural changes (Figs l and 2 ). Four patients only had numeric abnormalities without structural abnormalities. In the majority of the patients with an abnormal karyotype, there was a mixture of normal and abnormal metaphases (NA karyotypes), and only three patients had exclusively abnormal cells (AA karyotypes). Hyperdiploidy was observed in 39 patients, hypodiploidy in 19 patients (30% and 15% of patients with an assessable karyotype, respectively), and pseudodiploidy in eight patients. Of the 19 patients with hypodiploid karyotypes, seven patients were in relapse andor had a myelodysplastic syndrome, and four patients had primary resistance to alkylating agents. One patient had an associated amyloidosis and rapid death, and two patients had rapid death, respectively, caused by de novo PCL and solid tumor. Five patients responded to first-line therapy, three of whom responded to high-dose therapy (HDM, two patients; ABSCT, one patient). At the time of this report, only 5 of 19 hypodiploid patients are alive (four patients with a follow-up period less than 12 months). No patient with hypodiploidy had stage I MM. Eight hypodiploid patients had IgG M-component (including the patient with PCL), seven patients had IgA, and four patients had light-chain myeloma (including the patient with amyloidosis). Numeric changes were predominantly gains of chromosomes 3,5,7,9, 1 l, 15, and 19 and losses of chromosomes 8, 13, 14, 20, X, and Y (Fig 1) . The most frequent chromosomal loss was the loss of chromosome 13, observed in 22 patients (15%), including 18 patients at diagnosis (12%). Of the 18 patients with loss of chromosome 13 or del 13q at diagnosis, three were in stage I (one patient with amyloidosis), three were in stage 11, 10 were in stage 111, and two patients had plasma cell leukemia. Twelve patients produced IgG, five produced IgA, and one produced light chain only. The light chain was A in 11 patients and K in seven patients. Five patients were unassessable for response to treatment, including four patients who had rapid death of whom had a deletion at band 7q36, where the mdrl gene is localized. Two of these latter patients had newly diagnosed disease, and three were in relapse. All of these patients were resistant to chemotherapy at the time of cytogenetic analysis. Death occurred at 2 and 8 months for the patients at diagnosis and at 2, 8, and 1 1 months for the patients in relapse. Fourteen patients had structural abnormalities of chromosome 19, including 19q13 in eight patients (5%) and 19qter in two patients. Two patients had translocation t( I ; 16)(pl1 ;p1 l). DNA-derived ploidy (DNA index) was determined in 73 patients, including 62 patients at diagnosis. An abnormal DNA content (DNA index not equal to 1) was observed in 
patients (86%).
In patients with a chromosome number other than 46, there was a positive correlation between DNA content and modal chromosome number (Fig 3) . Impact of cytokine stimuldon. Of the I 5 I patients who had at least one type of stimulated culture, 6 of 1 I (55%) with GM-CSF cultures showed an abnormal karyotype: 47 of 1 I 1 (42%) with GM-CSF plus IL-6; 7 of 17 (41%) with IL-3 plus IL-6: and 4 of 14 (29%) with GM-CSF plus IL-3 plus IL-6. Of the 91 patients who had at their first evaluation a karyotype in both conditions, stimulated and unstimulated, 22 patients (24%) showed an abnormal karyotype in unstimulated culture. Among them. 10 showed a normal and one an unassessable karyotype in stimulated culture. Conversely, of the 38 patients with an abnormal karyotype in stimulated cultures. 27 (42%) presented a normal karyotype in unstimulated culture. Therefore. the abnormality detection rate was higher in stimulated than unstimulated cultures ( P < .01). Prognostic fuctor.s , f i w sun~ival. Median survival time from diagnosis was greater than 36 months for the whole series (N = 1 17) and 3 I .6 months for patients with an assessable karyotype. There was absolutely no statistically significant difference in the distributions of all other items between the group of 100 patients with an assessable karyotype and the 17 patients whose karyotype could not be evaluated. Patients with an abnormal karyotype at diagnosis had a 2.5-fold greater chance of death than those with a normal karyotype (RR, 2.5; 95% Cl, 1.2 to 5.4: P < .02), as shown in Fig 4. In the univariate analysis (Table 3) , the following characteristics were associated with a poor survival rate: age greater than 65 years, B substage, A light chain, microglobulin level greater than 6 mgL, LDH level greater than 300 I U L , Ki-67 greater than 6% abnormal karyotype, number of chromosomes less than 46, and absence of response to chemotherapy. The presence of a monosomy 13 was borderline significant. Moreover, when using continuous variables instead of categorized variables, an elevated blood level of pz microglobulin (RR, 1.067; 95% Cl, 1.028 to 1.106: P < .001), CRP (RR, 1.018; 95% CI, 1.006 to 1.032: P < .003), and Ki-67 (RR, 1.086: 95% Cl, 1.025 to 1. I SO; P < .04) and an evelated age (RR, 1.038: 95% Cl, 1 .005 to 1.072; P < .03) were associated with a short survival. Similar results were observed after logarithmic transformation for p2 microglobulin (RR, 6.2; 95% Cl, 2.0 to 19.1; P < .002) and Ki-67 (RR, 8.8: 95% Cl, 1.8 to 43.9: P < .007).
The multivariate analysis focused on the role of karyotype abnormality. When dealing with all variables measured for the 1 0 0 patients whose karyotype was interpretable and when using continuous variables as categorized, two factors only were selected successively: a A light chain ( P < .002) and an abnormal karyotype ( P < For .so
.003
-,003
.002
.
36
.07
40
08
.09
.001
Baseline category. t Category excluded from the analysis due to the number of patients. in the model provoking the disappearance of the abnormal karyotype role. When adding biologic variables to the model one by one, in most cases the same three variables were selected with the same effect on the relationship between survival and karyotype abnormality; whereas in the case of pz microglobulin blood level or Ki-67, the corresponding variable was selected with age and type of light chain. According to these results, the exact respective prognostic role of karyotype abnormality, stage above stage I, elevated p2 microglobulin blood level, or Ki-67 could not be ascertained.
The different observed selections were most likely related to patient selection by biologic variables not measured on all patients.
DISCUSSION
The 47% incidence of abnormal karyotypes found in this series for patients with newly diagnosed MM is the highest reported so far in a large series2~4~25~30 and is similar to our previous results! Only in the two small studies reported by Ferti et a13' (5 of 10 patients) and Chen et a13' (1 1 of 20 untreated patients) has such an incidence been previously observed. Although the differences observed in other studies may be partially accounted for by sampling errors, which are high because of the small sample size of the studies, this high incidence of chromosomal abnormalities was, in our opinion, attributable to the use of cytokine(s) stimulation. The percentage of abnormal karyotypes was higher in stimulated cultures, and the difference between stimulated and unstimulated cultures was statistically significant ( P < .01).
In a recent series, Weh et a13 identified a 30% abnormality rate overall and 26% for patients at diagnosis despite the addition of IL-6 to the cultures. Nevertheless, these investigators added only 25 IU/mL L-6, whereas we added 2,000 IU/mL in our cultures; we believe that this almost 100-For personal use only. on August 16, 2017. by guest www.bloodjournal.org From fold higher concentration may have accounted for our better results. Therefore, the present study is at the center of the evolving controversy concerning myeloma control by cytokines. There is now strong evidence that IL-6 is a major growth factor for malignant plasmablastic cells in vitro,""' and it has been established that GM-CSF and 1L-3 can synergize with IL-6 to support myeloma-cell proliferation.'," In vitro, the use of GM-CSF may allow the development of myeloma cell lines whose proliferation is dependent on addition of exogenous IL-6.7 In our cytogenetic work, we chose to use these new concepts, and, in fact, our results indirectly confirmed the potent role of these cytokines in myeloma growth control. In our experience, cytogenetic analysis of stimulated bone marrow cultures from healthy donors always led to normal karyotype (data not shown), and the cytogenetic abnormalities we found in myeloma patients after stimulation were qualitatively similar to those previously reported. In this work, we could not precisely determine the best cytokine stimulation, as multiple stimulated cultures could not routinely be performed for each patient. On the other hand, the finding that 10 patients who had an abnormal karyotype in unstimulated culture had a normal karyotype in stimulated culture is unexpected and stresses the complementarity of these two types of cultures in tumor cell analysis.
Chromosomal abnormalities were often complex, and hyperdiploidy was the most frequent finding. This study confirms and extends prior reports concerning gains of chromosomes 3, 5 , 7 , 9, 1 l , 15, and 19; loss of chromosome 13; and frequent structural changes of chromosomes 1 and 14. However, we observed a 5% incidence of 19q 13 abnormality, 12% of the patients with an abnormal karyotype. Such a relatively high incidence has not been reported so far, although 19q13 abnormality has been occasionally reported in MM'6 and plasma cell 1e~kemia.l~ In addition, we described a translocation t(1; 16)(pll;pl l ) in two patients.'x To our knowledge, this translocation has never been reported in hematologic malignancies, although structural abnormalities at the band 16pl1 have been described in diffuse largecell lymphoma.'6 Interestingly, the VH genes (VHl, VH2, and VH3) have been recently localized on band 16pl1 by in situ hybridization technique^.'^ Computerized image analysis was suitable for the determination of ploidy, and we identified a close relationship between DNA content as determined by cytogenetics and image analysis in patients with an abnormal karyotype. Overall, the incidence of cytogenetic abnormality was 87% using image analysis and only 51% using cytogenetics. Whether the use of other cytokine(s) stimulations or fluorescence in situ hybridization (FISH) techniques would lower this discrepancy remains to be determined.
This study also evaluates the prognostic value of abnormal cytogenetics in MM patients at diagnosis.
The prognostic factors in the series of 117 patients at diagnosis were those usually reported in MM: age, B substage, lambda light chain, LDH level, Ki-67 growth fraction, p2 microglobulin, and CRP levels, even if for this latter biologic variable the prognostic value was not significant when using cut-off values. Abnormal cytogenetics and a chromosome number less than 46 were associated with a shorter survival in Cox univariate analysis. In previous reports, it has been suggested that hypodiploidy is frequently associated with light chain-only production and with resistance to conventional chemotherapy.J.4".J' We did not confirm the preponderance of light chain isotype in our patients, but, overall, hypodiploidy was associated with a poor prognosis. In the analysis of cytogenetic results in relation to survival differences, the small sample size made it impossible to distinguish between one metaphase and many metaphases with structural abnormalities, numerical abnormalities only and numerical plus structural abnormalities, or between NN, AN, and AA karyotypes. The exact prognostic role of karyotype abnormality could not be clearly established by the multivariate analysis. Indeed, variable selection was clearly dependent on the way of coding continuous variables, with karyotype abnormality being preponderant with the type of light chain when these variables are categorized (although its role disappeared when using continuous variables). Moreover, variable selection was also dependent on the sample studied, which varied when studying biologic variables, which values were missing for about 10% of the patients. For these reasons. the respective roles of karyotype abnormality, stage I disease, age, and microglobulin level could not be clarified Although these data must be revisited in a larger series and with a longer follow up to ascertain the role of karyotype abnormality, the importance of this factor, when using cytokine-stimulated cultures of plasma cells, is clearly stated. Further studies are necessary to precisely define a high-risk population that may benefit from intensive therapeutic approaches.
